Patents by Inventor Nader Fotouhi

Nader Fotouhi has filed for patents to protect the following inventions. This listing includes patent applications that are pending as well as patents that have already been granted by the United States Patent and Trademark Office (USPTO).

  • Substituted phenyloxazolidinones for antimicrobial therapy
    Patent number: 11964949
    Abstract: The present invention relates to novel oxazolidinones (Formula I): or a pharmaceutically acceptable salt having ring A characterized by N-containing monocyclic, bicyclic or spirocyclic substituents, to their preparation, and to their use as drugs for treating Mycobacterium tuberculosis and other microbial infections, either alone or in combination with other anti-infective treatments.
    Type: Grant
    Filed: January 13, 2020
    Date of Patent: April 23, 2024
    Assignee: The Global Alliance for TB Drug Development, Inc.
    Inventors: Christopher B. Cooper, Haihong Huang, Dongfeng Zhang, Nader Fotouhi, Takushi Kaneko
  • INDOLE CARBOXAMIDE COMPOUNDS AND USE THEREOF FOR THE TREATMENT OF MYCOBACTERIAL INFECTIONS
    Publication number: 20230040909
    Abstract: Provided herein are compounds of Formula (I) as well as pharmaceutically acceptable salts thereof, wherein the substituents are as those disclosed in the specification. These compounds, and the pharmaceutical compositions containing them, are useful for the treatment of tuberculosis.
    Type: Application
    Filed: September 25, 2020
    Publication date: February 9, 2023
    Inventors: Takushi KANEKO, Nader FOTOUHI
  • AZAINDOLE CARBOXAMIDE COMPOUNDS FOR THE TREATMENT OF MYCOBACTERIAL INFECTIONS
    Publication number: 20230002372
    Abstract: Provided herein are compounds of Formula (I) and Formula (II): as well as pharmaceutically acceptable salts thereof, wherein the substituents are as those disclosed in the specification. These compounds, and the pharmaceutical compositions containing them, are useful for the treatment of tuberculosis.
    Type: Application
    Filed: September 25, 2020
    Publication date: January 5, 2023
    Inventors: Takushi KANEKO, Nader FOTOUHI
  • THIAZOLE CARBOXAMIDE COMPOUNDS AND USE THEREOF FOR THE TREATMENT OF MYCOBACTERIAL INFECTIONS
    Publication number: 20220396586
    Abstract: Provided herein are compounds of Formula (I) and Formula (II) as well as pharmaceutically acceptable salts thereof, wherein the substituents are as those disclosed in the specification. These compounds, and the pharmaceutical compositions containing them, are useful for the treatment of tuberculosis.
    Type: Application
    Filed: September 25, 2020
    Publication date: December 15, 2022
    Inventors: Takushi KANEKO, Nader FOTOUHI
  • Heteroaryltrifluoroborate compounds for the treatment of mycobacterial infections
    Patent number: 11261200
    Abstract: Provided herein are compounds of the formula (I): as well as pharmaceutically acceptable salts thereof, wherein the substituents are as those disclosed in the specification. These compounds, and the pharmaceutical compositions containing them, are useful for the treatment of tuberculosis.
    Type: Grant
    Filed: October 5, 2017
    Date of Patent: March 1, 2022
    Assignee: The Global Alliance for TB Drug Development, Inc.
    Inventors: Takushi Kaneko, Nader Fotouhi
  • SUBSTITUTED PHENYLOXAZOLIDINONES FOR ANTIMICROBIAL THERAPY
    Publication number: 20200148651
    Abstract: The present invention relates to novel oxazolidinones (Formula I): or a pharmaceutically acceptable salt having ring A characterized by N-containing monocyclic, bicyclic or spirocyclic substituents, to their preparation, and to their use as drugs for treating Mycobacterium tuberculosis and other microbial infections, either alone or in combination with other anti-infective treatments.
    Type: Application
    Filed: January 13, 2020
    Publication date: May 14, 2020
    Inventors: Christopher B. COOPER, Haihong HUANG, Dongfeng ZHANG, Nader FOTOUHI, Takushi KANEKO
  • Substituted phenyloxazolidinones for antimicrobial therapy
    Patent number: 10550092
    Abstract: The present invention relates to novel oxazolidinones (Formula I): or a pharmaceutically acceptable salt having ring A characterized by N-containing monocyclic, bicyclic or spirocyclic substituents, to their preparation, and to their use as drugs for treating Mycobacterium tuberculosis and other microbial infections, either alone or in combination with other anti-infective treatments.
    Type: Grant
    Filed: July 15, 2016
    Date of Patent: February 4, 2020
    Assignee: The Global Alliance for TB Drug Development, Inc.
    Inventors: Christopher B. Cooper, Haihong Huang, Dongfeng Zhang, Nader Fotouhi, Takushi Kaneko
  • HETEROARYLTRIFLUOROBORATE COMPOUNDS FOR THE TREATMENT OF MYCOBACTERIAL INFECTIONS
    Publication number: 20190276478
    Abstract: Provided herein are compounds of the formula (I): as well as pharmaceutically acceptable salts thereof, wherein the substituents are as those disclosed in the specification. These compounds, and the pharmaceutical compositions containing them, are useful for the treatment of tuberculosis.
    Type: Application
    Filed: October 5, 2017
    Publication date: September 12, 2019
    Inventors: Takushi Kaneko, Nader Fotouhi
  • SUBSTITUTED PHENYLOXAZOLIDINONES FOR ANTIMICROBIAL THERAPY
    Publication number: 20180179168
    Abstract: The present invention relates to novel oxazolidinones (Formula I): or a pharmaceutically acceptable salt having ring A characterized by N-containing monocyclic, bicyclic or spirocyclic substituents, to their preparation, and to their use as drugs for treating Mycobacterium tuberculosis and other microbial infections, either alone or in combination with other anti-infective treatments.
    Type: Application
    Filed: July 15, 2016
    Publication date: June 28, 2018
    Inventors: Christopher B. COOPER, Haihong HUANG, Dongfeng ZHANG, Nader FOTOUHI, Takushi KANEKO
  • Cell penetrating peptides to target EIF4E
    Patent number: 9409961
    Abstract: The present invention provides compounds to disrupt the eIF4E-eIF4G interaction and pharmaceutically acceptable salts of such compounds. Generally, the compounds are cell-penetrating peptides which bind mammalian initiation factor eIF4E (CPP-eIF4E), wherein the peptide comprises an amino acid sequence selected from the group consisting of SEQ ID NOS: 7, 9-11, 12-26, 27-44 and 45-51. More preferably, the amino acid sequence comprises at least 9 to about 40 amino acids and the mammalian initiation factor eIF4E is human initiation factor eIF4E.
    Type: Grant
    Filed: July 5, 2013
    Date of Patent: August 9, 2016
    Assignee: Hoffmann-La Roche Inc.
    Inventors: Waleed Danho, Nader Fotouhi, Yi Han, Wajiha Khan, Francesca Milletti, Huifeng Niu
  • CELL PENETRATING PEPTIDES WHICH BIND IRF5
    Publication number: 20160009772
    Abstract: The present invention comprises cell penetrating peptides that bind to interferon regulatory factor IRF5 and disrupt the IRF5 homo-dimerization and/or attenuate downstream signaling, and a method for screening peptides that inhibit IRF5. Generally, the cell penetrating peptides of the invention bind human interferon regulatory factor IRF5 (CPP-IRF5).
    Type: Application
    Filed: October 7, 2013
    Publication date: January 14, 2016
    Inventors: Julie Demartino, Nader Fotouhi, Ann Hoffman, Kuo-Sen Huang, Francesca Milletti, Sandip Panicker, Dinesh Srinivasan, Seng-Lai Tan
  • CELL PENETRATING PEPTIDES TO TARGET EIF4E
    Publication number: 20150166621
    Abstract: The present invention provides compounds to disrupt the eIF4E-eIF4G interaction and pharmaceutically acceptable salts of such compounds. Generally, the compounds are cell-penetrating peptides which bind mammalian initiation factor eIF4E (CPP-eIF4E), wherein the peptide comprises an amino acid sequence selected from the group consisting of SEQ ID NOS: 7, 9-11, 12-26, 27-44 and 45-51. More preferably, the amino acid sequence comprises at least 9 to about 40 amino acids and the mammalian initiation factor eIF4E is human initiation factor eIF4E.
    Type: Application
    Filed: July 5, 2013
    Publication date: June 18, 2015
    Inventors: Waleed Danho, Nader Fotouhi, Yi Han, Wajiha Khan, Francesca Milletti, Huifeng Niu
  • Neuropeptide-2 receptor (Y-2R) agonists and uses thereof
    Patent number: 8268784
    Abstract: Provided herein are neuropeptide-2 receptor agonists of the formula (I): as well as pharmaceutically acceptable salts, derivatives and fragments thereof, wherein the substituents are as those disclosed in the specification. X is 4-oxo-6-(1-piperazinyl)-3(4H)-quinazoline-acetic acid (Pqa). These compounds, and the pharmaceutical compositions containing them, are useful for the treatment of diseases such as, for example, obesity and diabetes.
    Type: Grant
    Filed: August 6, 2009
    Date of Patent: September 18, 2012
    Assignee: Hoffmann-La Roche Inc.
    Inventors: Karin Conde-Knape, Waleed Danho, George Ehrlich, Nader Fotouhi, David Charles Fry, Wajiha Khan, Anish Konkar, Cristina Martha Rondinone, Joseph Swistok, Rebecca Anne Taub, Jefferson Wright Tilley
  • Leukotriene Binhibitors
    Patent number: 8093385
    Abstract: Provided herein are compounds of the formula (I): as well as pharmaceutically acceptable salts thereof, wherein the substituents are as those disclosed in the specification. These compounds, and the pharmaceutical compositions containing them, are useful for the treatment of diseases such as, for example, COPD.
    Type: Grant
    Filed: July 28, 2008
    Date of Patent: January 10, 2012
    Assignee: Hoffmann-La Roche Inc.
    Inventors: Romyr Dominique, Nader Fotouhi, Paul Gillespie, Robert Alan Goodnow, Agnieszka Kowalczyk, Qi Qiao, Achyutharao Sidduri
  • NEUROPEPTIDE-2 RECEPTOR (Y-2R) AGONISTS
    Publication number: 20110172147
    Abstract: Provided herein are neuropeptide-2 receptor agonists of the formula (I): as well as pharmaceutically acceptable salts, derivatives and fragments thereof, wherein the substituents are as those disclosed in the specification. These compounds, and the pharmaceutical compositions containing them, are useful for the treatment of diseases such as, for example, obesity and diabetes.
    Type: Application
    Filed: March 25, 2011
    Publication date: July 14, 2011
    Inventors: Karin Conde-Knape, Waleed Danho, Nader Fotouhi, David Charles Fry, Wajiha Khan, Anish Konkar, Cristina Martha Rondinone, Joseph Swistok, Jefferson Wright Tilley
  • Chiral cis-imidazolines
    Patent number: 7964724
    Abstract: and the pharmaceutically acceptable salts and esters thereof, wherein X1, X2, X3, Y1, Y2 and R are described herein inhibit the interaction of MDM2 protein with a p53-like peptide and hence have anti proliferative activity.
    Type: Grant
    Filed: May 13, 2005
    Date of Patent: June 21, 2011
    Assignee: Hoffmann-La Roche Inc.
    Inventors: Nader Fotouhi, Gregory Jay Haley, Klaus B. Simonsen, Binh Thanh Vu, Stephen Evan Webber
  • MCH receptor antagonists
    Patent number: 7803816
    Abstract: Provided herein are compounds of the formula (I): as well as pharmaceutically acceptable salts thereof, wherein the substituents are as those disclosed in the specification. These compounds, and the pharmaceutical compositions containing them, are useful for the treatment of obesity, hyperphagia, anxiety, depression and related disorders and diseases.
    Type: Grant
    Filed: September 25, 2006
    Date of Patent: September 28, 2010
    Assignee: Hoffmann-La Roche Inc.
    Inventors: Steven Joseph Berthel, Shawn David Erickson, Nader Fotouhi, Robert Francis Kester, Kyungjin Kim, Steven Gregory Mischke, Yimin Qian, Kshitij Chhabilbhai Thakkar, Jefferson Wright Tilley, Hong Wang
  • Neoropeptide-2-Receptor (Y-2R) Agonists
    Publication number: 20100179093
    Abstract: Provided herein are neuropeptide-2 receptor agonists of the formula (I): as well as pharmaceutically acceptable salts, derivatives and fragments thereof, wherein the substituents are as those disclosed in the specification. These compounds, and the pharmaceutical compositions containing them, are useful for the treatment of diseases such as, for example, obesity and diabetes.
    Type: Application
    Filed: November 2, 2009
    Publication date: July 15, 2010
    Inventors: Waleed Danho, Nader Fotouhi, David Charles Fry, Wajiha Khan, Joseph Swistok, Jefferson Wright Tilley
  • NEUROPEPTIDE-2 RECEPTOR (Y-2R) AGONISTS AND USES THEREOF
    Publication number: 20100137223
    Abstract: Provided herein are neuropeptide-2 receptor agonists of the formula (I): as well as pharmaceutically acceptable salts, derivatives and fragments thereof, wherein the substituents are as those disclosed in the specification. X is 4-oxo-6-(1-piperazinyl)-3(4H)-quinazoline-acetic acid (Pqa). These compounds, and the pharmaceutical compositions containing them, are useful for the treatment of diseases such as, for example, obesity and diabetes.
    Type: Application
    Filed: August 6, 2009
    Publication date: June 3, 2010
    Inventors: Karin Conde-Knape, Waleed Danho, George Ehrlich, Nader Fotouhi, David Charles Fry, Wajiha Khan, Anish Konkar, Cristina Martha Rondinone, Joseph Swistok, Rebecca Anne Taub, Jefferson Wright Tilley
  • Adamantyl-pyrazole carboxamides as inhibitors of 11?-hdroxysteroid dehydrogenase
    Patent number: 7728029
    Abstract: Provided herein are compounds of the formula (I): as well as pharmaceutically acceptable salts thereof, wherein the substituents are as those disclosed in the specification. These compounds, and the pharmaceutical compositions containing them, are useful for the treatment of diseases such as, for example, type II diabetes mellitus and metabolic syndrome.
    Type: Grant
    Filed: March 14, 2007
    Date of Patent: June 1, 2010
    Assignee: Hoffmann-La Roche Inc.
    Inventors: Kevin William Anderson, Nader Fotouhi, Paul Gillespie, Robert Alan Goodnow, Jr., Kevin Richard Guertin, Nancy-Ellen Haynes, Michael Paul Myers, Sherrie Lynn Pietranico-Cole, Lida Qi, Pamela Loreen Rossman, Nathan Robert Scott, Kshitij Chhabilbhai Thakkar, Jefferson Wright Tilley, Qiang Zhang